Streetbeat News

Products Services

ECOR

ElectroCore's GammaCore Therapy will continue to be listed in the U.K's National Health Service Supply Chain Catalogue for an additional two years until March 17, 2026. The listing, which commenced on June 4, 2019, was initially scheduled to terminate on March 18, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:03 pm

INMB

INmune Bio Inc. will present new biomarker and feasibility data from its Phase 1b study, supporting the use of XPro in treating Alzheimer's disease, at the Clinical Trials on Alzheimer's Disease Conference from October 24-27.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:01 pm

RZLT

The European Medicines Agency has granted Priority Medicines (PRIME) eligibility to Rezolute's RZ358 for the treatment of Congenital Hyperinsulinism. This could potentially expedite the development and review of the drug.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:01 pm

LSTA

Lisata Therapeutics has announced that the European Medicines Agency has granted orphan drug designation to LSTA1 for the treatment of pancreatic cancer.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:01 pm

ACN

SAP

Accenture (NYSE:ACN) is partnering with SAP to help organizations adopt generative AI across their core business processes. The collaboration aims to create AI-enabled solutions that can enhance an organization's investment in SAP technology by improving business performance and employee productivity, and accelerating time to value with SAP S/4HANA Cloud.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:00 pm

AAPL

TCEHY

Apple Inc.'s CEO, Tim Cook, has made an unannounced visit to China amid reports of declining iPhone 15 sales in the country. During his visit, Cook praised Tencent Holdings Ltd.'s popular game 'Honor of Kings', which earned $2.5 billion in 2020, making it the highest-grossing title on the App Store. This visit comes at a time when Apple's sales are reportedly declining in China, with some estimates suggesting a 'sharp double-digit' fall compared to the iPhone 14 series.

Portfolio Pulse from Rounak Jain

October 17, 2023 | 11:57 am

JNJ

NVO

In an interview cited by Reuters, J&J's CFO Wolk stated that the company currently lacks the scientific expertise to venture into obesity drug development.

Portfolio Pulse from Charles Gross

October 17, 2023 | 11:54 am

GLUE

Monte Rosa Therapeutics has announced interim data from the Phase 1 dose escalation part of its ongoing Phase 1/2 study of MRT-2359 in patients with MYC-driven solid tumors.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 11:48 am

VIGL

Vigil Neuroscience has initiated a Phase 1 trial in healthy volunteers to evaluate VG-3927, a potential treatment for Alzheimer's disease. The first participant has been dosed.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 11:46 am

XAIR

Beyond Cancer, an affiliate of Beyond Air, has published preclinical data showing that its proprietary technology reduces immunosuppression and creates a favorable microenvironment that can contribute to immune potentiation.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 11:45 am